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Virus-like particles (VLPs) have been widely used in vaccine development over the last decades [1]. In fact, 
there are already several approved human vaccines against viruses that use recombinant VLPs as antigen, e.g. 
for hepatitis B virus and human papillomavirus [2]. Vaccination remains the most effective way to prevent 
infection with influenza viruses. However, their constant antigenic drift requires an annual update of the 
seasonal vaccine to prevent influenza epidemics [3-4]. To use the full potential of VLPs as vaccines efficient 
upstream processing as well as downstream processing (DSP) trains need to be established. The latter is of 
particular importance as it often accounts for the major biomanufacturing costs. Here we describe the 
establishment of an improved DSP unit train platform, adapted from virus particles to influenza VLPs, using 
pseudo-affinity sulfated cellulose membrane adsorbers (SCMA) [5]. An initial clarification step prepares the bulk 
for the subsequent purification steps. SCMA performance was optimized using a design of experiments (DoE) 
approach. More than 80% of the product was recovered with removal of host cell protein and DNA above 89% 
and 80%, respectively. This represents a significant improvement in performance compared to the traditional 
use of ion exchangers commercially available. Using this SCMA platform for influenza virus particles purification 
we were able to speed up the process by decreasing the number of DSP steps, to improve the scale-up and to 
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